SkinPen is the one with a real cosmetic FDA indication. Morpheus8 is not. That is the reverse of what most clinic pages imply, so it is worth stating precisely.
SkinPen Precision was granted through a De Novo request, DEN160029, on 1 March 2018. It was the first microneedling device authorised for marketing in the US, and it created the device category itself (21 CFR 878.4430, product code QAI). Its current indication (K202243, 2 April 2021) reads: "intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II - IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older."
Morpheus8's clearances name no cosmetic use at all. The 2019 clearance (K192695) is for "Electrocoagulation and Hemostasis." A 2023 clearance (K231790) changed the wording to "coagulation/contraction of soft tissue or hemostasis," which InMode announced in July 2024. Acne scars, wrinkles, laxity, cellulite, stretch marks and the double chin appear in none of them. Treating those with Morpheus8 is off-label, which is legal and routine.
The physical difference is heat. SkinPen makes a channel with a needle and stops there. Morpheus8 makes the channel and then delivers radiofrequency current into the skin at the depth the operator chose. That added thermal injury is what the tightening claims rest on, and it is also why the treatment costs more and carries a different risk list.
De Novo DEN160029, granted March 2018; the device that created the microneedling category.
A rebuilt version of InMode's older Fractora platform, cleared using Fractora3D as the predicate.
Thousands of vertical channels trigger the normal wound-healing response - fibroblast activity, new collagen, elastin remodelling.
Bipolar RF flows between pins. The pins are coated except the distal 0.5 mm, so the energy is released below the surface.
The pivotal study used a maximum needle length of 2.5 mm, and the labelling instructs treatment at depths of up to 2.5 mm.
InMode's manual lists 0.5 mm fixed (Resurfacing tip), 1-4 mm (12-pin Prime), 1-7 mm (24-pin) and 2-7 mm (40-pin Body). The highest depth in any FDA summary is 7.0 mm.
It does not tighten lax skin and does not reach or heat fat, so it has no contouring effect.
Acne scars are the best-evidenced use of RF microneedling as a class - one split-face trial found it roughly as effective as fractional CO2 with less downtime and fewer pigment events (Li 2026).
The exact wording is quoted above. The neck restriction is easy to misreport - only the acne-scar half covers all skin types.
No cosmetic indication is named in any Morpheus8 clearance.
Mild swelling and pinpoint bleeding on the day. This is the conventional clinical description, not a labelled figure.
In one study of the device class, redness occurred in 100% of patients and swelling in 30% (Navyadevi 2024). Another put downtime at 3-4 days (Clementoni 2016). Barrier function returns to baseline by about day 7 (Wu 2022).
Clinical convention, not a labelled figure.
"Generally 3-5 sessions are needed for mild to moderate depth settings."
The main driver is the tip. RF microneedling tips are single-use and expensive, and the deeper or larger applicators cost more per tip. That cost passes straight into the price, and it is the main reason RF microneedling is priced well above mechanical microneedling.
For Morpheus8, the best dated price source is RealSelf's cost page, updated 10 May 2024: an average of $1,861, with prices starting at $549 for one small area and a full series costing upwards of $4,000. That figure comes from 124 self-reported consumer prices - it is not a survey, not audited, and not a random sample. No professional society publishes an average price for RF microneedling, and there is no comparable dated published figure for SkinPen.
Almost no published study used Morpheus8. A PubMed search returns about 16 records for the name, and no randomised controlled trial of the device was found. The evidence people are shown when they search "Morpheus8" was generated on other machines - Lutronic, Jeisys, Pollogen, Lumenis and unnamed devices. The class evidence is real, but it is not this brand's evidence.
Two further limits apply to the whole RF microneedling class. The longest properly measured follow-up in the literature is 6 months; claims of one to three years have no published source. And in the FDA's own postmarket database (MAUDE, 2013-2025), fat loss was 26 of 224 reported events - a proportion of reports with no denominator, so it cannot be turned into a per-patient risk, but it is a documented complication that the marketing does not discuss. A separate study that measured the submental fat layer after RF microneedling found no significant change (Wu 2024).
Both break the skin, so both create an entry route for infection and both can wake up the cold sore virus.